Following the approval in 1986 of Orthoclone OKT3, the first therapeutic monoclonal antibody product, a class of new protein-based therapeutic drugs was introduced and became the dominant product class within the biopharmaceutical market.
Today, several monoclonal antibodies have been approved for the treatment of a variety of diseases, ranging from those that target orphan disease indications with a small patient population, to those that target much larger patient populations and demographics, such as for oncology, asthma, and rheumatoid arthritis.

In Issue 8 of The Altascientist, we explore the role of anti-drug antibodies (ADAs) in therapeutic development, their impact on efficacy, and detection strategies, including:

• Challenges encountered in ADA assays
• Cell-based or non-cell-based assays to measure neutralization
• How Altasciences can help